Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GALR2 | O43603 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25764471 | 0.88 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2KDM4EKMT2AHTT | |
| SCHEMBL4502908 | 0.88 | ALDH1A1 (0.51) | ALDH1A1NQO2SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL16637409 | 0.85 | KDM4E (0.53) | ALDH1A1SMN1; SMN2KDM4EKMT2AHTT | |
| SCHEMBL12021198 | 0.83 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4EKMT2AHTT | |
| SCHEMBL4858316 | 0.83 | ALDH1A1 (0.53) | ALDH1A1NQO2SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL21857249 | 0.81 | GAA (0.50) | ALDH1A1SMN1; SMN2KDM4EKMT2AHTT | |
| SCHEMBL17881940 | 0.81 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2KDM4EKMT2AHTT | |
| SCHEMBL2849661 | 0.80 | CFTR (0.45) | ALDH1A1NQO2SMN1; SMN2KMT2AHTT | |
| SCHEMBL23540576 | 0.79 | ALDH1A1 (0.41) | ALDH1A1NQO2SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL29476351 | 0.79 | ALDH1A1 (0.41) | ALDH1A1NQO2SMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| CN-118076612-A | Sulfur-containing heteroaromatic tricyclic KRAS inhibitors | 医睿世康药业研发公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4347603-A1 | SULFUR-CONTAINING HETEROAROMATIC TRICYCLIC KRAS INHIBITORS | Erasca, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2001070228-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 3870/4885NQO2 781/4885SMN1; SMN2 2284/4885 |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | KRAS, NRAS, HRAS | ALDH1A1 2548/4885NQO2 435/4885SMN1; SMN2 3697/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4009/4885NQO2 249/4885SMN1; SMN2 2243/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4009/4885NQO2 249/4885SMN1; SMN2 2243/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885NQO2 1318/4885SMN1; SMN2 1888/4885 |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | DHFR, TYMS, TYMP | ALDH1A1 564/4885NQO2 284/4885SMN1; SMN2 1205/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885NQO2 1318/4885SMN1; SMN2 1888/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885NQO2 1318/4885SMN1; SMN2 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.